β3 Receptors: Role in cardiometabolic disorders

28Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pharmacological and molecular approaches have shown that an atypical β-adrenoceptor (AR), called β3-AR, that is distinct from β1-ARs and β2-ARs, exists in some tissues in heterogeneous populations such as β3a-ARs and β3b-ARs. β3-ARs belong to a superfamily of receptors linked to guanine nucleotide binding proteins (G proteins). The β3-AR gene contains two introns whereas the β1-AR and β2-AR genes are intronless, leading to splice variants. β3-ARs can couple to Gi and Gs and they are reported to be present in brown adipose tissue, vasculature, the heart, among other tissues. β3-ARs cause vasodilation of microvessels in the islets of Langerhans and may participate in the pathogenesis of cardiac failure, during which modification of β1-AR and β2-AR expression occurs. The development of β3-AR agonists has led to the elaboration of promising new drugs, including antiobesity and antidiabetic drugs. This article reviews the various pharmacological actions of β3-ARs and their clinical implications for diabetes and cardiovascular diseases. © 2011, SAGE Publications. All rights reserved.

Cite

CITATION STYLE

APA

Bhadada, S. V., Patel, B. M., Mehta, A. A., & Goyal, R. K. (2011). β3 Receptors: Role in cardiometabolic disorders. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018810390259

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free